Last reviewed · How we verify
NCT05172102: Covid-19
Quality of Life and Lung Function on Post Covid-19 Patient
NA trial testing breathing exercise, Aerobic exercises in COVID-19 in 40 participants. Completed in 30 March 2023.
20 March 2023
Quick facts
| Lead sponsor | Qassim University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 20 December 2021 |
| Primary completion | 20 March 2023 |
| Estimated completion | 30 March 2023 |
| Sites | 1 location across Saudi Arabia |
Drugs / interventions tested
- breathing exercise, Aerobic exercises
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Qassim University
Who can join
Adults 20 to 30, female only, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gaining a greater understanding of how the breathing exercise combined with aerobic and strengthening exercises will affects lung function and quality of life in post covid-19 persons
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Pulmonary Telerehabilitation Program Improves Exercise Capacity and Quality of Life in Young Females Post-COVID-19 Patients.
Alsharidah AS, Kamel FH, Alanazi AA, Alhawsah EA, et al · · 2023 · cited 6× · PMID 37980910 · DOI 10.5535/arm.23060
Verify or expand the search:
- PubMed search for NCT05172102
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Qassim University trials
Trials by the same sponsor.
- NCT07400432 — Acute Effects of Moderate-Intensity Continuous Exercise Versus HIIT on Cognitive Performance and Psychophysiological Res · NA · enrolling by invitation
- NCT07055659 — Enhancing Oral Hygiene in Children Through an Innovative Motivational Model · NA · active not recruiting
- NCT06873230 — Assessment of Empathy Levels in Dental Hygiene Students and Interns · not yet recruiting
- NCT06891495 — Evaluating an AI-Generated Health Podcast · recruiting
- NCT07443007 — Effects of Balance, Plyometric, and Combined Plyometric-Balance Training in Pediatric Burn Survivors · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05172102 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qassim University
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172102.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing